IL108261A - שיטה והתקן לטיפול בדם או מרכיב דם - Google Patents

שיטה והתקן לטיפול בדם או מרכיב דם

Info

Publication number: IL108261A
Authority: IL; Israel
Prior art keywords: platelet; filter; platelets; leukocyte; fiber
Prior art date: 1988-02-17

Application number

IL10826189A

Other languages

English (en)

Other versions

IL108261A0 (en

Original Assignee

Pall Corp

Cove Glen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-17

Filing date

1989-02-16

Publication date

1996-10-31

1988-04-25 Priority claimed from US07/185,993 external-priority patent/US4880548A/en

1989-02-16 Application filed by Pall Corp, Cove Glen filed Critical Pall Corp

1994-04-12 Publication of IL108261A0 publication Critical patent/IL108261A0/xx

1996-10-31 Publication of IL108261A publication Critical patent/IL108261A/he

Links

238000000034 method Methods 0.000 title description 55
210000004369 blood Anatomy 0.000 title description 32
239000008280 blood Substances 0.000 title description 32
239000012503 blood component Substances 0.000 title description 7
239000000835 fiber Substances 0.000 description 149
210000000265 leukocyte Anatomy 0.000 description 134
239000003634 thrombocyte concentrate Substances 0.000 description 131
238000012360 testing method Methods 0.000 description 73
238000011084 recovery Methods 0.000 description 63
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 54
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical group CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 53
239000000243 solution Substances 0.000 description 49
239000011148 porous material Substances 0.000 description 47
239000000178 monomer Substances 0.000 description 46
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 40
239000012530 fluid Substances 0.000 description 32
239000007788 liquid Substances 0.000 description 31
239000000975 dye Substances 0.000 description 27
239000000047 product Substances 0.000 description 26
239000002253 acid Substances 0.000 description 23
229920001707 polybutylene terephthalate Polymers 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000000306 component Substances 0.000 description 16
238000009826 distribution Methods 0.000 description 15
-1 polytetrafluoroethylene Polymers 0.000 description 15
238000009736 wetting Methods 0.000 description 15
238000011161 development Methods 0.000 description 14
238000001179 sorption measurement Methods 0.000 description 14
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
230000037452 priming Effects 0.000 description 13
238000001914 filtration Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
238000012986 modification Methods 0.000 description 11
230000004048 modification Effects 0.000 description 11
239000002245 particle Substances 0.000 description 11
230000008569 process Effects 0.000 description 11
230000005855 radiation Effects 0.000 description 11
229920005989 resin Polymers 0.000 description 11
239000011347 resin Substances 0.000 description 11
230000006835 compression Effects 0.000 description 10
238000007906 compression Methods 0.000 description 10
239000000203 mixture Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 9
125000000129 anionic group Chemical group 0.000 description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
239000000463 material Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000000926 separation method Methods 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000011144 upstream manufacturing Methods 0.000 description 8
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
238000007664 blowing Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
229920000728 polyester Polymers 0.000 description 7
229920002994 synthetic fiber Polymers 0.000 description 7
239000012209 synthetic fiber Substances 0.000 description 7
206010037660 Pyrexia Diseases 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000005259 measurement Methods 0.000 description 6
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
206010060935 Alloimmunisation Diseases 0.000 description 5
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
230000000712 assembly Effects 0.000 description 5
238000000429 assembly Methods 0.000 description 5
230000008859 change Effects 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
238000011109 contamination Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
108010073385 Fibrin Proteins 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229920001343 polytetrafluoroethylene Polymers 0.000 description 4
239000004810 polytetrafluoroethylene Substances 0.000 description 4
229920006395 saturated elastomer Chemical group 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010049003 Fibrinogen Proteins 0.000 description 3
102000008946 Fibrinogen Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000427 antigen Substances 0.000 description 3
238000002617 apheresis Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010276 construction Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000000428 dust Substances 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000155 melt Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
238000003908 quality control method Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
238000007789 sealing Methods 0.000 description 3
XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
206010043554 thrombocytopenia Diseases 0.000 description 3
230000003582 thrombocytopenic effect Effects 0.000 description 3
POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010002961 Aplasia Diseases 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
229920002292 Nylon 6 Polymers 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
208000003441 Transfusion reaction Diseases 0.000 description 2
229920006397 acrylic thermoplastic Polymers 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
150000001767 cationic compounds Chemical class 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
238000011049 filling Methods 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
230000005484 gravity Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
125000005395 methacrylic acid group Chemical group 0.000 description 2
238000002156 mixing Methods 0.000 description 2
JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920000139 polyethylene terephthalate Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000011045 prefiltration Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000001453 quaternary ammonium group Chemical group 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229920003002 synthetic resin Polymers 0.000 description 2
239000000057 synthetic resin Substances 0.000 description 2
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000035899 viability Effects 0.000 description 2
238000000733 zeta-potential measurement Methods 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
206010073306 Exposure to radiation Diseases 0.000 description 1
208000032371 Glanzmann thrombasthenia 1 Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 1
101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
108010000020 Platelet Factor 3 Proteins 0.000 description 1
206010073391 Platelet dysfunction Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 1
108010081391 Ristocetin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000000392 Thrombasthenia Diseases 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027276 Von Willebrand disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000001206 effect on leukocytes Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012632 extractable Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920005668 polycarbonate resin Polymers 0.000 description 1
239000004431 polycarbonate resin Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000306 polymethylpentene Polymers 0.000 description 1
239000011116 polymethylpentene Substances 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000002310 reflectometry Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229950004257 ristocetin Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000012815 thermoplastic material Substances 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
208000009852 uremia Diseases 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
238000003466 welding Methods 0.000 description 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
External Artificial Organs (AREA)

IL10826189A 1988-02-17 1989-02-16 שיטה והתקן לטיפול בדם או מרכיב דם IL108261A (he)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15689488A	1988-02-17	1988-02-17
US07/185,993 US4880548A (en)	1988-02-17	1988-04-25	Device and method for separating leucocytes from platelet concentrate
IL8931489A IL89314A (he)	1988-02-17	1989-02-16	התקן ושיטה להפרדת כדוריות דם לבנות מתרכיז

Publications (2)

Publication Number	Publication Date
IL108261A0 IL108261A0 (en)	1994-04-12
IL108261A true IL108261A (he)	1996-10-31

Family

ID=27271359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10826189A IL108261A (he)	1988-02-17	1989-02-16	שיטה והתקן לטיפול בדם או מרכיב דם

Country Status (1)

Country	Link
IL (1)	IL108261A (he)

1989
- 1989-02-16 IL IL10826189A patent/IL108261A/he not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL108261A0 (en)	1994-04-12

Legal Events

Date	Code	Title
1997-03-18	FF	Patent granted
1997-09-30	KB	Patent renewed
1999-07-14	KB	Patent renewed
2000-12-06	RH	Patent void
2003-04-10	KB	Patent renewed
2007-05-21	KB	Patent renewed

Publication	Publication Date	Title
EP0329303B2 (en)	2001-09-26	Device and method for separating leukocytes from platelet concentrate
JP2555722B2 (ja)	1996-11-20	血液および血液成分の白血球含量を低下させるための装置および方法
US5501795A (en)	1996-03-26	Device for depletion of the leucocyte content of blood and blood components
JP2541340B2 (ja)	1996-10-09	血液および血液成分の白血球含量を低下させる装置および方法
US4925572A (en)	1990-05-15	Device and method for depletion of the leukocyte content of blood and blood components
US4923620A (en)	1990-05-08	Device for depletion of the leukocyte content of blood and blood components
US5258126A (en)	1993-11-02	Method for obtaining platelets
EP0267286A1 (en)	1988-05-18	Filter medium for selectively removing leucocytes
US4976861A (en)	1990-12-11	Method for determining the wetting characteristic of a porous medium
US5360545A (en)	1994-11-01	Filter for obtaining platelets
CN1073614A (zh)	1993-06-30	从生物体液分离血浆的方法和装置
CA1335713C (en)	1995-05-30	Device and method for separating leucocytes from platelet concentrate
KR20190026842A (ko)	2019-03-13	혈액 처리 필터용 필터 요소, 혈액 처리 필터 및 백혈구 제거 방법
US7217365B2 (en)	2007-05-15	Blood filtration methods
GB2246432A (en)	1992-01-29	Testing filter media
AU624095B2 (en)	1992-06-04	Depletion of leukocyte from blood
GB2248193A (en)	1992-04-01	Blood filter
IL106893A (he)	1996-05-14	שיטה והתקן להפרדת חומר)ים( מנוזל שנועד להחדרה לחולה